1. Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia
- Author
-
Naoto Takahashi, M Fukazawa, Stuart A. Scott, Yasuhiro Maeda, T Katayama, M Sakai, Miwako Narita, Makoto Kashimura, F Urase, Masatomo Miura, Masayoshi Masuko, Fumihiko Monma, Hisashi Wakita, Yasushi Miyazaki, Tatsuo Furukawa, Kazuhiro Nishii, K Fujikawa, Naoyuki Katayama, Kenichi Sawada, and K Ishige
- Subjects
Adult ,Male ,medicine.medical_specialty ,Myeloid ,Adolescent ,medicine.drug_class ,Gastroenterology ,Piperazines ,Tyrosine-kinase inhibitor ,Cohort Studies ,Young Adult ,Asian People ,Pharmacokinetics ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Aged ,Aged, 80 and over ,Pharmacology ,business.industry ,Myeloid leukemia ,Imatinib ,Odds ratio ,Middle Aged ,medicine.disease ,Leukemia ,Pyrimidines ,Treatment Outcome ,Imatinib mesylate ,Endocrinology ,medicine.anatomical_structure ,Benzamides ,Leukemia, Myeloid, Chronic-Phase ,Imatinib Mesylate ,Female ,business ,medicine.drug - Abstract
Despite the outstanding results generally obtained with imatinib mesylate (IM) in the treatment of chronic myeloid leukemia (CML), some patients show a poor molecular response. To evaluate the relationship between steady-state trough plasma IM concentration (IM-C(min)) and clinical response in CML patients, we integrated data from six independent Japanese studies. Among 254 CML patients, the mean IM-C(min) was 1,010.5 ng/ml. Importantly, IM-C(min) was significantly higher in patients who achieved a major molecular response (MMR) than in those who did not (P = 0.002). Multivariate analysis showed that an MMR was associated with both age (odds ratio (OR) = 0.97 (0.958-0.995); P = 0.0153) and with IM-C(min) (OR = 1.0008 (1.0003-1.0015); P = 0.0044). Given that patients with IM-C(min) values >1,002 ng/ml had a higher probability of achieving an MMR in our large cohort (P = 0.0120), the data suggest that monitoring of IM levels in plasma may improve the efficacy of IM therapy for CML patients.
- Published
- 2010
- Full Text
- View/download PDF